[Comment] Clinical benefit and the Trump administration's cancer medicine reforms

In December, 2025, the Trump administration announced completion of the second cycle of historic price negotiations between US Medicare and pharmaceutical manufacturers.1 Concurrently, it released plans to establish international reference pricing to lower the costs of cancer drugs and other medicines in Medicare to levels in peer countries.2 These policy changes could have important effects on access to cancer medicines…